Herantis Pharma Plc, Press Release, 27 May 2022 at 13:00 EEST
Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that interim CEO Frans Wuite will be presenting at the Redeye Growth Day on June 2th, 2022.
Redeye Growth Day
The presentation will be live on the Redeye platform at 9:25 a.m. CEST
Follow this link to the event: Redeye Growth Day.
The presentations will be available via digital libraries, which are accessible to event participants only.
Please contact the conference organizers, or send an email to firstname.lastname@example.org, if you wish to schedule a meeting with Herantis.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit https://www.herantis.com